CLLS - Cellectis S.A.

QQQ $ 468.16 $ -5.41 (-1.13 %)

DIA $ 411.36 $ -1.55 (-0.38 %)

SPY $ 558.32 $ -3.26 (-0.58 %)

TLT $ 97.88 $ -0.12 (-0.12 %)

GLD $ 231.76 $ -1.64 (-0.7 %)

Previous Close

$ 2.37

Open

$ 2.40

Bid

$ 2.36 x 100

Ask

-- x --

Day's Range

$ 2.40 - $ 2.41

52 Week Range

$ 0.96 - $ 3.77

Volume

32,450

Average Volume

Market Cap

170.05M

Beta (5Y Monthly)

$ 2.02

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cellectis Publishes A 'Molecular Therapy' ...
08/26/2024 20:34:05

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

Cellectis Q2 2024 Adj EPS $(0.24) Beats $(...
08/06/2024 21:19:38

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by ...

$cellectis-announces-fda-grants-orphan-drug-designation-to-clls52-alemtuzumab-for-lymphodepletion-regimen-in-ucart22-evaluated-in-balli-01-clinical-trial-for-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia$

Cellectis Announces FDA Grants Orphan Drug...
08/01/2024 21:03:51

Cellectis Announces FDA Grants Orphan Drug...
07/25/2024 20:42:38

Cellectis Publishes Scientific Article Dem...
06/20/2024 20:31:49

Cellectis Reports Publication Of A Scienti...
06/12/2024 20:38:08

Oppenheimer Maintains Outperform on Cellec...
06/12/2024 13:26:23

Oppenheimer analyst Hartaj Singh maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $11 to...

Cellectis Says European Commission Has Gra...
06/04/2024 20:31:34

UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in BALLI-01, a Phase 1/2 open-label dose-esc...

JMP Securities Reiterates Market Outperfor...
05/31/2024 15:28:05

JMP Securities analyst Silvan Tuerkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $6 price ta...

Cellectis Q1 Adj $(0.14) Beats $(0.33) Est...
05/28/2024 20:33:46

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.33) by ...

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
05/07/2024 12:06:20

Cellectis Announces Completion Of AstraZen...
05/06/2024 08:11:35

As part of the Additional Investment, AstraZeneca subscribed today for 10,000,000 "class A" convertible preferred share...

Cellectis Appoints Arthur Stril As Interim...
05/02/2024 21:35:55

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

Cellectis Q4 2023 GAAP EPS $(0.64) Misses ...
04/29/2024 20:49:30

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.26) b...

Cellectis To Present Data On TALEN Editing...
04/22/2024 20:38:50

Cellectis Publishes Novel Intronic Gene Ed...
04/10/2024 20:31:47

Cellectis Announces Two Poster Presentatio...
04/08/2024 20:36:46

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

Cellectis Announces The Execution Of The S...
11/15/2023 08:26:20

Cellectis Q3 2023 Adj EPS $(0.36) Beats $(...
11/06/2023 22:03:20

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by ...

Earnings Scheduled For November 6, 2023
11/06/2023 13:24:53

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on ...